Qualidade de vida no glioblastoma após a introdução da temozolomida: uma revisão sistemática
DOI:
https://doi.org/10.33448/rsd-v11i15.37205Palavras-chave:
Qualidade de Vida; Glioblastoma; Temozolomida.Resumo
Introdução: Gliomas são tumores primários do sistema nervoso central com padrão agressivo de progressão com prognóstico ruim quanto a sobrevida e qualidade de vida. O tratamento padrão atual consiste em cirurgia com excisão máxima associado a radioterapia e quimioterapia, pautada majoritariamente pelo uso da temozolomida. Desde sua introdução, a qualidade de vida dos pacientes submetidos a essa terapia não foi amplamente objetivada e avaliada. Objetivo: Verificar a qualidade de vida dos pacientes portadores de glioblastoma após a introdução da temozolomida nos protocolos terapêuticos. Métodos: Foi conduzida revisão sistemática da literatura guiada pelo protocolo PICO e PRISMA; consultadas as bases de dados do PubMed, Medline e Lilacs. Resultados: Inicialmente encontrados 77 estudos, após critérios de seleção foram analisados 35 artigos. Não foi encontrada alteração estatisticamente significativa na qualidade de vida global nos estudos que analisaram a terapia com temozolomida frente às diferentes terapias controle. Conclusão: A associação da temozolomida à cirurgia e radioterapia se mostrou neutra, sem impactos negativos ou positivos consideráveis na qualidade de vida dos pacientes portadores de glioblastoma.
Referências
Arakawa, Y. et al. (2021). A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 ( AgedGlio -PIII), BMC Cancer, 21 (1), 1-8.
Armstrong, T. S. et al. (2013). Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma, Journal of Clinical Oncology, 31 (32), 4076-4084.
Baba, M. A., Adali, N. (2021). Neurocognitive state and quality of life of patients with glioblastoma in Mediterranean countries: a systematic review. Annals of Palliative Medicine, 10 (11), 11980-11993.
Badruddoja, M. A. et al. (2017). Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma, Cancer Chemotherapy and Pharmacology, 80 (4), 715-721.
Brada, M. et al. (2001). Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse, Annals of Oncology, 12 (2), 259-266.
Brada, M. et al. (2005). Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide, Annals of Oncology, 16 (6), 942-949.
Braun, K. & Ahluwalia, M. S. (2017). Treatment of glioblastoma in older adults, Current Oncology Reports, 19 (12), 1-7.
Campos, J. A. D. B. et al. (2018). European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30: models factorials in patients Brazilians with cancer, Einstein (Sao Paulo), 16 (1), 1-8.
Caroli, M. et al. (2007). Temozolomide in glioblastoma: results of administration first relapse and in newly diagnosed cases. Is an alternative schedule to concomitant protocol still proposed?, Journal of Neuro-oncology, 84 (1), 71-77.
Chibbaro, S. et al. (2004). Temozolomide as a first-line agent in treating high-grade gliomas: phase II study, Journal of Neuro-oncology, 67 (1), 77-81.
Chiu, Leonard et al. (2012). Quality of life in patients with primary and metastatic brain cancer as reported in the literature using the EORTC QLQ-BN20 and QLQ-C30, Expert Review of Pharmacoeconomics & Outcomes Research, 12 (6), 831-837.
Davis, M. E. & Mulligan Stoiber, A. M. (2011). Glioblastoma multiforme : enhancing survival and quality of life, Clinical Journal of Oncology Nursing, 15 (3), 291-297.
Dinnes, J., Cave, C., Huang, S. & Milne, R. (2002). A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma, British Journal of Cancer, 86 (4), 501-505.
Domenech, M., Hernandez, A. & Balana, C. (2021). The need for geriatric scales in glioblastoma. Aging (Albany NY), 13 (14), 17959-17960.
Hamilton, D. A. (2006). Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma. Cancer Treatment Reviews, 32 (6), 483-486.
Hanna, C. et al.(2020). Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis, Cochrane Database of Systematic Reviews, 3 (3), 1-133.
Karachi, A., Dastmalchi, F., Mitchel, D. A. & Rahman, M. (2018). Temozolomide for immunomodulation in the treatment of glioblastoma, Neuro-Oncology, 20 (12), 1566-1572.
Khan , R. B. et al. (2002). A phase II study of extended low-dose temozolomide in recurrent malignant gliomas, Neuro-oncology, 4 (1), 39-43.
Kocher, M. et al. (2008). Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma, Strahlentherapie und Onkologie, 184 (11), 572-579.
Kong, D. S. et al. (2010). Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma, Neuro-oncology, 12 (3), 289-296.
Lim, M., Xia, Y., Bettegowda, C. & Weller, M. (2018). Current state of immunotherapy for glioblastoma, Nature Reviews Clinical Oncology, 15 (7), 422-442.
Lombardi, G. et al. (2018). Quality of life perception, cognitive function, and psychological status in a real-world population of glioblastoma patients treated with radiotherapy and temozolomide, American Journal of Clinical Oncology, 41 (12), 1263-1271.
Lukas, R. V., Razis, E. D., Huse, J. T. (2021). An international perspective on the management of glioblastoma, Chinese Clinical Oncology, 10 (4), 107.
Malmstrom, A. et al. (2012). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomized , phase 3 trial, The Lancet Oncology, 13 (9), 916-926.
McBain, C. et al. (2021). Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis, Cochrane Database of Systematic Reviews, 5 (1), 1-135.
Minniti, G. et al. (2009). Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma, Journal of Neuro-oncology, 91 (1), 95-100.
Minniti, G. et al. (2013). Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide, International Journal of Radiation Oncology, Biology, Physics, 86 (2), 285-291.
Mir, T., Pond, G. & Greenspoon, J. N. (2021). Outcomes in elderly patients with glioblastoma multiforme treated with short-course radiation alone compared to short-course radiation and concurrent and adjuvant temozolomide based on performance status and extent of resection, Current Oncology, 28 (4), 2399-2408.
Osoba, D., Brada, M, Yung, W. K. & Prado, M. (2000). Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme, Journal of Clinical Oncology, 18 (7), 1481-1491.
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D. et al. (2021). The PRISMA 2020 statement : an updated guideline for reporting systematically reviews, BMJ, 372 (71), 1-9.
Paulsen, F. et al. (1999). Chemotherapy in the treatment of recurrent glioblastoma multiforme : ifosfamide versus temozolomide . Journal of Cancer Research and Clinical Oncology, 125 (7), 411-418.
Pedretti, S. et al. (2019). Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial, Journal of Neuro-Oncology, 143 (3), 447-455.
Perry, J. R. et al. (2017). Short-course radiation plus temozolomide in elderly patients with glioblastoma, New England Journal of Medicine, 376 (11), 1027-1037.
Pessini, L. (2009). Distanásia: até quando investir sem agredir?, Revista Bioética, 4 (1), 1-11.
Reddy, K. et al. (2013). Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide, Journal of Neuro-oncology, 114 (1), 111-116.
Reyes-Botero, G. et al. (2018). Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial (ATAG), The Oncologist, 23 (5), 524-e44.
Santos, C. M. C., Pimenta, C. A. M., Nobre, M. R. C. (2007). A estratégia PICO para a construção da pergunta de pesquisa e busca de evidências. Revista Latino-Americana de Enfermagem, 15 (1), 508-511.
Schafer, N. et al. (2018). Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT- nonmethylated glioblastoma, Neuro-oncology, 20 (7), 975-985.
Sim, H. W., Nowak, A. K., Lwin, Z. & Khasraw, M. (2021). Management of glioblastoma: an Australian perspective, Chinese Clinical Oncology, 10 (4), 42.
Stahl, P. et al. Health-related quality of life and emotional well-being in patients with glioblastoma and their relatives, Journal of Neuro-Oncology, 149 (2), 347-356.
Taphoorn, M. J. B. et al. (2005). Health- related quality of life in patients with glioblastoma: a randomized controlled trial, The Lancet Oncology, 6 (12), 937-944.
Taphoorn, M. J. B. et al. (2015). Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide , and radiotherapy in newly diagnosed glioblastoma, Journal of Clinical Oncology, 33 (9), 2166-2175.
Taphoorn, M. J. B. et al. (2018). Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial, JAMA Oncology, 4 (4), 495-504.
Weller, J. et al. (2019). Health-related quality of life and neurocognitive functioning with lomustine – temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma ( CeTeG /NOA-09): A randomized , multicentre , open-label, phase 3 trial, The Lancet Oncology, 20 (10), 1444-1453.
Wirsching, H.G., Galanis, E. & Weller, M. (2016). Glioblastoma, Hand Clin Neuro, 134 (1), 381-397.
YIin, A. et al. (2013). Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis, Plos One, 8 (9), e74242.
Yin, A. et al. (2014). A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients, Journal of Neuro-oncology, 116 (2), 315-324.
Yung, W. K. A et al. (200). A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse, British Journal of Cancer, 83 (5), 588-593.
Zhu, J. J. et al. (2017). Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma, Journal of Neuro-oncology, 135 (3), 545-552.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2022 Thales Augusto Oliveira Dias; Dyecika Souza Couto; Edvaldo José Rodrigues Cardoso
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
